Search results for "Pulmonary and Respiratory Medicine"

showing 10 items of 1498 documents

Physical capacity in performing daily activities is reduced in scleroderma patients with early lung involvement

2015

Background and Aims Patients with systemic sclerosis (SSc) often complain reduced capacity at submaximal exercise; conversely, physical capacity in performing daily duties has never been measured in SSc. The aim of this study is to evaluate this performance and its correlates, in patients with SSc compared with healthy controls, in a free-living setting. Methods Twenty-seven outpatients with stable SSc and 11 controls were recruited. Physical activity was assessed by portable multiple sensor device (SenseWear Armband) worn for at least 6 days. Physical activity duration (PAD; in minutes) for non-sedentary activities and physical activity level (PAL = total daily energy/resting energy expend…

030203 arthritis & rheumatologyPulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtyActivities of daily livingmedicine.diagnostic_testbusiness.industrymedicine.diseasePhysical activity levelScleroderma03 medical and health sciences0302 clinical medicine030228 respiratory systemDLCOInternal medicinemedicinePhysical therapyCardiologyImmunology and AllergyResting energy expenditurebusinessBioelectrical impedance analysisBody mass indexGenetics (clinical)The Clinical Respiratory Journal
researchProduct

International BEAT-PCD Consensus Statement for Infection Prevention and Control for Primary Ciliary Dyskinesia in collaboration with ERN-LUNG PCD Cor…

2021

Introduction In primary ciliary dyskinesia (PCD) impaired mucociliary clearance leads to recurrent airway infections and progressive lung destruction, and concern over chronic airway infection and patient-to-patient transmission is considerable. So far, there has been no defined consensus on how to control infection across centres caring for patients with PCD. Within the BEAT-PCD network, COST Action and ERS CRC together with the ERN-Lung PCD core a first initiative has now been taken towards creating such a consensus statement. Methods A multidisciplinary international PCD expert panel was set up to create a consensus statement for infection prevention and control (IP&C) for PCD, covering …

:Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores]Infeccions respiratòries en els infantsPrimary Ciliary DyskinesiaStatement (logic)Respiratory SystemMULTICENTERRECOMMENDATIONS0302 clinical medicineOriginal Research ArticlesPandemicSTENOTROPHOMONAS-MALTOPHILIAInfection control:Pathological Conditions Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease [DISEASES]030212 general & internal medicinePrimary ciliary dyskinesiaMalalties transmissibles - Transmissió:Environmental Health::Health::Environmental Illness::Communicable Diseases::Communicable Disease Control [PUBLIC HEALTH]FOUNDATIONbiologyTransmission (medicine)R:Congenital Hereditary and Neonatal Diseases and Abnormalities::Congenital Abnormalities::Abnormalities Multiple::Ciliopathies::Congenital Hereditary and Neonatal Diseases and Abnormalities::Ciliary Motility Disorders [DISEASES]:afecciones patológicas signos y síntomas::procesos patológicos::atributos de la enfermedad::enfermedad crónica [ENFERMEDADES]:salud ambiental::salud::enfermedad ambiental::enfermedades transmisibles::control de enfermedades transmisibles [SALUD PÚBLICA]medicine.anatomical_structureMedicinePatient representativesLife Sciences & BiomedicinePulmonary and Respiratory Medicinemedicine.medical_specialty3610 Medicine & health:enfermedades y anomalías neonatales congénitas y hereditarias::anomalías congénitas::anomalías múltiples::ciliopatías::enfermedades y anomalías neonatales congénitas y hereditarias::trastornos de la motilidad ciliar [ENFERMEDADES]:Other subheadings::Other subheadings::/prevention & control [Other subheadings]03 medical and health sciencesotorhinolaryngologic diseasesmedicineIntensive care medicineScience & TechnologyCYSTIC-FIBROSISLungbusiness.industryPSEUDOMONAS-AERUGINOSAMalalties cròniques - PrevencióCAREEFFICACYmedicine.diseasebiology.organism_classificationrespiratory tract diseases030228 respiratory systemNontuberculous mycobacteria610 Medizin und GesundheitbusinessERJ Open Research
researchProduct

Dependence of plasma pH on oxygen saturation

1969

Abstract The influence of haemoglobin oxygenation on the pH value of the blood plasma of healthy adolescents was investigated at 38°C by varying the parameters CO2 pressure, Hb concentration and buffer bases. A total of 5000 measurements gave the following results: 1. 1. The pHs difference between oxygenated and deoxygenated blood increases with diminishing CO2 pressure and with increasing Hb concentration. There is a linear relation between the pHs changes and the O2 saturation of the haemoglobin. 2. 2. Quantitatively these relationships can be expressed by the following equation: δpHs = (8 − pH ox − log 0.03 Pco 2 ) · [Hb] 225 · (100 − So 2 100 where ΔpHs is the pHs difference between par…

Acid-Base EquilibriumPulmonary and Respiratory MedicineAdolescentPhysiologyChemistryPartial PressureAnalytical chemistryOxygenationVenous bloodPlasmaBuffersCarbon DioxideHydrogen-Ion ConcentrationOxygenBicarbonatesHemoglobinsBloodBiochemistryBlood plasmaLinear relationHumansBase excessOxygen saturationBlood phRespiration Physiology
researchProduct

Symptom variability and control in COPD: Advantages of dual bronchodilation therapy

2017

Abstract Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by usually progressive development of airflow obstruction that is not fully reversible. While most patients will experience symptoms throughout the day or in the morning upon awakening, many patients do not experience their symptoms as constant but report variability in symptoms during the course of the day or over time. Symptom variability adversely affects patients' health status and increases the risk of COPD exacerbations. Methods We examined data from the literature on symptom variability and control in patients with COPD, with focus on the use of inhaled bronchodilator therapy wi…

Aclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Pulmonary and Respiratory MedicineAclidiniumHealth StatusVital CapacityHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumeFormoterol FumarateBronchodilatorBronchodilationFormoterol030212 general & internal medicineAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital CapacityLung functionCOPDbiologyChronic obstructive pulmonary diseaseTropaneLamaBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeInhalationAdministrationCombinationDisease ProgressionDrug Therapy CombinationDrugHumanmedicine.drugAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classSymptom variabilitySocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioDose-Response RelationshipPulmonary Disease03 medical and health sciencesDrug TherapyAdministration InhalationmedicineHumansIntensive care medicineAdrenergic beta-2 Receptor AgonistsBronchodilator AgentDose-Response Relationship Drugbusiness.industryMuscarinic antagonistDual bronchodilator therapymedicine.diseasebiology.organism_classificationLung functionrespiratory tract diseasesAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital Capacity; Pulmonary and Respiratory MedicineDual bronchodilation030228 respiratory systemQuality of LifeFormoterolbusinessTropanesRespiratory Medicine
researchProduct

Early management of COPD: Where are we now and where do we go from here? a delphi consensus project

2019

Fabiano Di Marco,1 Piero Balbo,2 Francesco de Blasio,3 Vittorio Cardaci,4 Nunzio Crimi,5 Giuseppe Girbino,6 Girolamo Pelaia,7 Pietro Pirina,8 Pietro Roversi,9 Pierachille Santus,10,11 Nicola Scichilone,12 Alessandro Vatrella,13 Patrizio Pasqualetti,14 Mauro Carone15 1Department of Health Sciences, University of Milan, Respiratory Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy; 2SC Malattie dell’Apparato Respiratorio, AOU Maggiore della Carità, Novara, Italy; 3Respiratory Medicine and Pulmonary Rehabilitation Section, Clinic Center S.p.A. Private Hospital, Department of Medicine and Health Sciences “V Tiberio”, University of Molise, Campobasso, It…

Adrenergic beta-2 Receptor AgonistPulmonary and Respiratory Medicinedrug combinationspractice guidelines as topicConsensuPredictive Value of Testbronchodilator therapy; dyspnea; italy; respiratory symptoms; adrenal cortex hormones; adrenergic beta-2 receptor agonists; adult; bronchodilator agents; consensus; delphi technique; drug combinations; early diagnosis; early medical intervention; evidence-based medicine; female; humans; italy; male; middle aged; muscarinic antagonists; practice guidelines as topic; predictive value of tests; pulmonary disease; chronic obstructive; surveys and questionnaires; treatment outcomeadrenal cortex hormonesSettore MED/10 - Malattie Dell'Apparato RespiratorioInternational Journal of Chronic Obstructive Pulmonary DiseasedyspnoeaAdrenal Cortex HormonePulmonary Disease Chronic ObstructivemaleDrug CombinationEarly Diagnosiitalymiddle agedSurveys and Questionnairehumansmuscarinic antagonistsBronchodilator AgentOriginal Researchearly medical interventionpulmonary diseaselcsh:RC705-779chronic obstructiveHealth Policyadultbronchodilator agentsEnvironmental and Occupational Healthrespiratory symptomsbronchodilator therapylcsh:Diseases of the respiratory systemdyspneaBronchodilator therapy; Dyspnea; Italy; Respiratory symptoms; Pulmonary and Respiratory Medicine; Health Policy; Public Health Environmental and Occupational Healthpredictive value of testsMuscarinic AntagonistfemaleconsensusRespiratory symptomsurveys and questionnairestreatment outcomePublic Healthdelphi techniqueadrenergic beta-2 receptor agonistsevidence-based medicineHumanearly diagnosis
researchProduct

The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory suppor…

2016

Shahid Husain, MD, MS, Amparo Sole, MD, PhD, Barbara D. Alexander, MD, MHS, Saima Aslam, MD, MS, Robin Avery, MD, Christian Benden, MD, Eliane M. Billaud, PharmD, PhD, Daniel Chambers, MBBS, MD, Lara Danziger-Isakov, MD, Savitri Fedson, MD, Kate Gould, MD, Aric Gregson, MD, Paolo Grossi, MD, PhD, Denis Hadjiliadis, MD, Peter Hopkins, MD, Me-Linh Luong, MD, Debbie J.E. Marriott, MD, Victor Monforte, MD, Patricia Munoz, MD, PhD, Alessandro C. Pasqualotto, MD, PhD, Antonio Roman, MD, Fernanda P. Silveira, MD, Jeffrey Teuteberg, MD, MS, Stephen Weigt, MD, Aimee K. Zaas, MD, MHS, Andreas Zuckerman, MD, and Orla Morrissey, MD, PhD

Adult0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialty2747 TransplantationHeart-Lung Transplantation030106 microbiology610 Medicine & health030230 surgery2705 Cardiology and Cardiovascular Medicine03 medical and health sciencesPostoperative Complications0302 clinical medicinePrevalencemedicineHumansAssisted CirculationChildTransplantationbusiness.industryIncidence2746 SurgerySurgeryMycoses2740 Pulmonary and Respiratory MedicineAdult; Child; Humans; Incidence; Mycoses; Postoperative Complications; Prevalence; Assisted Circulation; Heart-Lung Transplantation; Surgery; Pulmonary and Respiratory Medicine; Cardiology and Cardiovascular Medicine; TransplantationSurgery10178 Clinic for PneumologyCardiology and Cardiovascular MedicinebusinessHumanitiesThe Journal of Heart and Lung Transplantation
researchProduct

Sleep apnoea severity independently predicts glycaemic health in nondiabetic subjects: the ESADA study

2014

Abstract: Obstructive sleep apnoea (OSA) is associated with increased risk of dysglycaemia but the intimate link of these conditions with obesity makes discerning an independent relationship between them challenging. Glycosylated haemoglobin (HbA1c) levels predict adverse cardiovascular outcomes in nondiabetics but there is a lack of population-level data exploring the relationship of HbA1c with OSA. A cross-sectional analysis of 5294 participants in the multinational European Sleep Apnoea Cohort (European Sleep Apnoea Database) study was performed, assessing the relationship of OSA severity with HbA1c levels in nondiabetic subjects, with adjustment for confounding factors. HbA1c levels cor…

AdultBlood GlucoseMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentCross-sectional studyPolysomnographyintermittent hypoxia insulin resistance diabetes obesityBlood PressurePolysomnographySettore MED/10 - Malattie Dell'Apparato Respiratoriota3111Young Adultstomatognathic systemInternal medicineDiabetes MellitusmedicineHumansProspective StudiesSleep studyHypoxiaAgedAged 80 and overGlycated HemoglobinSleep Apnea ObstructiveAnthropometrymedicine.diagnostic_testbusiness.industryConfoundingSleep apneaOdds ratioMiddle Agedmedicine.diseasenervous system diseasesrespiratory tract diseasesEuropeCross-Sectional StudiesTreatment OutcomeQuartileCardiovascular DiseasesHyperglycemiaMultivariate AnalysisCohortPhysical therapyFemaleHuman medicinebusinessEuropean Respiratory Journal
researchProduct

Age is associated with asthma phenotypes

2017

Background and objective: The relationship between age and asthma phenotypes is important as population is ageing, asthma is becoming common in older ages and recently developed treatments for asthma are guided by phenotypes. The aim of this study is to evaluate whether age is associated with specific asthma phenotypes. Methods: This is a cross-sectional study. We included subjects with asthma of varied degrees of severity. Subjects underwent spirometry, skin prick test to aeroallergens, answered the Asthma Control Questionnaire and had blood samples collected. We performed binary logistic regression analysis to evaluate whether age is associated with asthma phenotypes. Results: We enrolled…

AdultCross-Sectional StudieMalePulmonary and Respiratory Medicinelung function testSkin TestasthmaMiddle AgedSettore MED/10 - Malattie Dell'Apparato RespiratorioallergyPhenotypeSpirometryeosinophilAge FactorFemaleAgedHuman
researchProduct

Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma

2003

Background: Inhaled corticosteroids (ICS) affect many inflammatory pathways in asthma but have little impact on cysteinyl leukotrienes. This may partly explain persistent airway inflammation during chronic ICS treatment and failure to achieve adequate asthma control in some patients. This double blind, randomised, parallel group, non-inferiority, multicentre 16 week study compared the clinical benefits of adding montelukast to budesonide with doubling the budesonide dose in adults with asthma. Methods: After a 1 month single blind run in period, patients inadequately controlled on inhaled budesonide (800 µg/day) were randomised to receive montelukast 10 mg + inhaled budesonide 800 µg/day (n…

AdultCyclopropanesMalePulmonary and Respiratory MedicineBudesonideAdolescentmedicine.drug_classAcetatesSulfidesFluticasone propionatechemistry.chemical_compoundDouble-Blind Methodimmune system diseasesAdministration InhalationHumansMedicineSingle-Blind MethodAnti-Asthmatic AgentsBudesonideMontelukastAgedAsthmaLeukotriene E4business.industryMiddle Agedmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeEditorialchemistryAnesthesiaQuinolinesCorticosteroidDrug Therapy CombinationFemaleOnset of actionSalmeterolbusinessmedicine.drugThorax
researchProduct

Once-daily tiotropium Respimat® 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma

2015

SummaryIntroductionOnce-daily tiotropium Respimat® 5 μg is an efficacious add-on therapy to inhaled corticosteroids (ICS) with or without long-acting β2-agonists in patients with symptomatic asthma. The objective of this study was to investigate whether the dosing regimen of tiotropium (once- versus twice-daily), delivered via the Respimat® SoftMist™ inhaler, affected 24-h bronchodilator efficacy and safety versus placebo Respimat® in patients with asthma who were symptomatic despite medium-dose ICS therapy.MethodsA randomised, double-blind, placebo-controlled, crossover study with 4-week treatment periods of tiotropium 5 μg (once-daily, evening) and 2.5 μg (twice-daily, morning and evening…

AdultEstoniaMalePulmonary and Respiratory MedicineVital capacityRespimatEveningAdolescentmedicine.drug_classPlaceboDouble-Blind MethodRisk FactorsAnticholinergic drugForced Expiratory VolumeGermanyBronchodilatorAdministration InhalationmedicineHumansDosingDosing regimenTiotropium BromideAgedCzech RepublicAsthmaLong-acting bronchodilatorCross-Over StudiesDose-Response Relationship Drugbusiness.industryTiotropiumInhalerMiddle Agedmedicine.diseaseLatviaAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBronchodilator efficacyAustriaAnesthesiaFemalebusinessRespiratory Medicine
researchProduct